Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment

Abstract

Matrix metalloproteinase-9 (MMP-9) is involved in blood-brain barrier (BBB) disruption in active multiple sclerosis (MS), while MMP-2 seems to be associated with the chronic progressive phase of the disease. Recombinant interferon beta-1a (rIFNβ-1a) is effective in restoring the BBB. We studied the relationships between serum MMP-9, MMP-2, TIMP-1 and TIMP-2 and different magnetic resonance imaging (MRI) measures of disease activity in MS patients during treatment with rIFNβ-1a. Twenty-one relapsing-remitting (RR) MS patients underwent longitudinally simultaneous blood withdrawals and MRI (before and after standard dose (SD) and triple dose (TD) of gadolinium (Gd)) examinations before and during 48 weeks of rIFNβ-1a (Rebif® 22 mcg three times a week) treatment. Serum MMP-9, MMP-2, TIMP-1 and TIMP-2 were measured, MMP-9 to TIMP-1 and MMP-2 to TIMP-2 ratios were calculated and the numbers of Gd-SD, Gd-TD, new-Gd-SD, new-Gd-TD and new-T2 lesions counted. Serum MMP-9/TIMP-1 ratio (P< 0.0001), as well as the numbers of ‘active’ lesions (P ranging from 0.0004 to 0.005) decreased during treatment. Moreover, serum MMP-9/TIMP-1 ratio proved to be a good positive predictor (estimate= 0.85; P> 0.05) of the numbers of MRI Gd-TD active lesions. These data confirm that serum MMP-9/TIMP-1 ratio may be viewed as a reliable marker and may be predictive of MRI activity in RR MS.

Keywords

gadolinium triple dose interferon beta MMP-9/TIMP-1 MMP-2/TIMP-2 MRI multiple sclerosis

Get full access to this article

View all access options for this article.

References

Leppert D , Lindberg RLP , Kappos L , Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis . Brain Res Rev 2001; 36: 249-257 .

Chandler S , Miller KM , Clements JM , Lury J , Corkill D , Anthony DCC et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: and overview . J Neuroimmunol 1997; 72: 155-161 .

Yong VW , Power C , Forsyth P , Edwards DR. Metalloproteinases in biology and pathology of the nervous system . Nat Rev Neurosci 2001; 2: 502-511 .

Brew K , Dinakarpandian D , Nagase H. Tissue inhibitors of matalloproteinases: evolution, structure and function . Biochim Biophys Acta 2000; 1477: 267-283 .

Rosenberg GA , Dencoff JE , Correa N , Reiners M , Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury . Neurology 1996; 46: 1626-1632 .

Lee MA , Palace J , Stabler G , Ford J , Gearing A , Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study . Brain 1999; 122: 191-197 .

Leppert D , Ford J , Stabler G , Grygar C , Lienert C , Huber S et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis . Brain 1998; 121: 2327-2334 .

Waubant E , Goodkin DE , Gee L , Bacchetti P , Sloan R , Stewart T et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis . Neurology 1999; 53: 1397-1401 .

Avolio C , Ruggieri M , Giuliani M , Liuzzi GM , Leante R , Riccio P et al. Serum MMP-2 and MMP-9 are elevated in different Multiple Sclerosis subtypes . J Neuroimmunol 2003; 136: 46-53 .

10.

Stone LA , Frank JA , Albert PS , Bash C , Smith ME , Maloni H et al. The effects of interferon-b on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis . Ann Neurol 1995; 37: 611-619 .

11.

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular Interferon b-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 1996; 39: 285-294 .

12.

Li DKB , Paty DW and the UBC MS/MRI Analysis Research Group and the PRISMS Study Group . Magnetic resonance imaging results of the PRISMS trial: a randomized, double blind, placebo-controlled study of Interferon-b1a in relapsing-remitting multiple sclerosis . Ann Neurol 1999; 46: 197-206 .

13.

European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis . Lancet 1998; 352: 1491-1497 .

14.

Rudick RA , Cookfair DL , Simonian NA , Ransohoff RM , Richert JR , Jacobs LD et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNβ-1a) for relapsing multiple sclerosis . J Neuroimmunol 1999; 93: 8-14 .

15.

Leppert D , Waubant E , Burk MR , Oksenberg JR , Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis . Ann Neurol 1996; 40: 846-852 .

16.

Stuve O , Dooley NP , Uhm JH , Antel JP , Francis GS , Williams G et al. Interferon b-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9 . Ann Neurol 1996; 40: 853-863 .

17.

Uhm JH , Dooley NP , Stuve O , Francis GS , Duquette P , Antel JP et al. Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy . Ann Neurol 1999; 46: 319-324 .

18.

Lou J , Gasche Y , Zheng L , Giroud C , Morel P , Clements J et al. Interferon-b inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer . Lab Invest 1999; 79: 1015-1025 .

19.

Trojano M , Avolio C , Liuzzi GM , Ruggieri M , Defazio G , Liguori M et al. Changes of serum ICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS . Neurology 1999; 53: 1402-1408 .

20.

Waubant E , Gee L , Miller K , Stabler G , Goodkin D. IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis . J Interferon Cytokine Res 2001; 21: 181-185 .

21.

Waubant E , Goodkin D , Bostrom A , Bacchetti P , Hietpas J , Lindberg R et al. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS . Neurology 2003; 60: 52-57 .

22.

Filippi M , Yousry T , Campi A , Kandziora C , Colombo B , Voltz R et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS . Neurology 1996; 46: 379-384 .

23.

Filippi M , Rovaris M , Capra R , Gasperini C , Yousry TA , Sormani MP et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials . Brain 1998; 121: 2011-2020 .

24.

Filippi M , Rocca MA , Rizzo G , Horsfield MA , Rovaris M , Minicucci L et al. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium . Neurology 1998; 50: 1289-1293 .

25.

Poser CM , Paty DW , Scheinberg L , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocol . Ann Neurol 1983; 13: 227-231 .

26.

Miller DH , Barkhof F , Berry I , Kappos L , Scotti G , Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines . J Neurol Neurosurg Psychiatry 1991; 54: 683-688 .

27.

Rovaris M , Bastianello S , Capra R , Comi G , Yousry TA , Filippi M. Correlations between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis . Magn Reson Imaging 1999; 17: 985-988 .

28.

Filippi M , Rovaris M , Capra R , Gasperini C , Prandini F , Martinelli V et al. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology . J Neurol Neurosurg Psychiatry 1999; 67: 386-389 .

29.

Bar-Or A , Nuttall RK , Duddy M , Alter A , Kim HJ , Ifergan I et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis . Brain 2003; 126: 2738-2749 .